Payment overview · 2025
General Payments
$719.02
24 reported records · 11 companies
Healthcare provider profile · identity verified
Jennifer Gee, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PALM BAY, FL · NPI 1205239944
Verified facts
What the public records show
CMS Open Payments records show Jennifer Gee, ARNP received $719.02 in general payments during 2025 across 24 reported records.
Regeneron Healthcare Solutions, Inc. accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $265.51 | 36.9% | 8 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $100.78 | 14.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.09 | 8.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $58.54 | 8.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.01 | 7.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.12 | 6.5% | 2 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $40.33 | 5.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $32.06 | 4.5% | 1 | 2025 |
| Cochlear Americas | Unresolved — no canonical attribution shown | $26.43 | 3.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.90 | 2.5% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $17.25 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $719.02 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $273.38 | 8 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $100.78 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $60.09 | 1 | 2025 |
Source payment records
|
|||||
| TULA Normalized: tula |
Device | Smith+Nephew, Inc. | $58.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.12 | 2 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| BAHA Normalized: baha |
Device | Cochlear Americas | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Normalized: cochlear nucleus ci632 cochlear implant with slim modiolar electrode |
Device | Cochlear Americas | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| OSIA OSI300 IMPLANT Normalized: osia osi300 implant |
Device | Cochlear Americas | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 51 |
| Lisinopril | Lisinopril | 137 | 47 |
| Losartan Potassium | Losartan Potassium | 133 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 39 |
| Omeprazole | Omeprazole | 124 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 27 |
| Alprazolam | Alprazolam | 92 | 20 |
| Gabapentin | Gabapentin | 82 | 32 |
| Famotidine | Famotidine | 81 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 24 |
| Tramadol Hcl | Tramadol Hcl | 69 | 18 |
| Metformin Hcl | Metformin Hcl | 68 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Sertraline Hcl | Sertraline Hcl | 58 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 14 |
| Jardiance | Empagliflozin | 50 | 13 |
| Montelukast Sodium | Montelukast Sodium | 50 | 20 |
| Clonazepam | Clonazepam | 47 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 19 |
| Ozempic | Semaglutide | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 46 | 16 |
| Furosemide | Furosemide | 45 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Atenolol | Atenolol | 38 | 13 |
| Trazodone Hcl | Trazodone Hcl | 37 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Allopurinol | Allopurinol | 35 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 14 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | 12 |
| Metformin Hcl Er | Metformin Hcl | 33 | 14 |
| Prednisone | Prednisone | 33 | 27 |
| Risperidone | Risperidone | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | 13 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 18 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Cefdinir | Cefdinir | 21 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 19 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $719.02 · 24 records | Regeneron Healthcare Solutions, Inc. | BAHA, COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE, Cequa, DUPIXENT, MIEBO, NEFFY, NUCALA, OSIA OSI300 IMPLANT, QULIPTA, TEZSPIRE, TULA, UBRELVY, VYZULTA, XHANCE, XIIDRA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error